Latest Commercial Strategy News

Page 10 of 10
Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.
Ada Torres
Ada Torres
31 Jan 2025
Kingsland Minerals secures a $2.56 million strategic investment from Quinbrook Infrastructure Partners, marking a pivotal step in advancing the Leliyn Graphite Project with binding offtake and renewable energy agreements.
Maxwell Dee
Maxwell Dee
30 Jan 2025
LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.
Ada Torres
Ada Torres
30 Jan 2025
Opthea Limited has spotlighted Sozinibercept as a potential game-changer in wet age-related macular degeneration (AMD) therapy, presenting compelling clinical data and a clear path to U.S. market entry.
Victor Sage
Victor Sage
29 Jan 2025
InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.
Ada Torres
Ada Torres
24 Jan 2025
Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.
Ada Torres
Ada Torres
24 Jan 2025
Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.
Victor Sage
Victor Sage
17 Jan 2025
Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.
Ada Torres
Ada Torres
16 Jan 2025
Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.
Ada Torres
Ada Torres
15 Jan 2025